How pharma giants compare in 2024?
As the year draws to a close, pharmaceutical companies have released their Q3 reports, offering a snapshot of the industry's current landscape, including market capitalization and trailing twelve-month (TTM) revenues.
While the market caps of these giants are staggering, their revenues appear relatively moderate by comparison. Leading the pack are Eli Lilly and Novo Nordisk, signaling the industry's strong focus on GLP-1 agonists and treatments for obesity and diabetes.
The rankings also highlight the role of niche innovations in shaping the future of pharma. Here are the top pharmaceutical companies by market cap:
- Eli Lilly – $715.3B
- Novo Nordisk – $467.5B
- Johnson & Johnson – $373.2B
- AbbVie – $323.3B
- Merck – $257.1B
- Roche – $233.0B
- Novartis – $211.5B
- AstraZeneca – $209.7B
- Amgen – $152.1B
- Pfizer – $148.5B
- Sanofi – $121.6B
- Vertex Pharmaceuticals – $120.6B
- Bristol Myers Squibb – $120.1B
- Gilead Sciences – $115.4B
- CSL – $90.1B
Source: companiesmarketcap
